Stock Region Penny Picks
đ Watchlist Updates You Donât Want to Miss! Tuesday, June 17, 2025.
đ Watchlist Updates You Donât Want to Miss! Tuesday, June 17, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Regionâs real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The content in this newsletter is for informational purposes only. Itâs important to do your own research and consult with a financial advisor before making any investment decisions. Stocks carry risks, and past performance isnât indicative of future results.
Hi Stock Region fam,
There's no shortage of action in the market this week! Buckle up, because our watchlist is brimming with updates that could shake things up. Grab your favorite beverage, and let's dissect whatâs happening with your favorite tickers (and maybe discover a new one).
đ©ș Biotech Bonanza
$ACXP (Acurx Pharmaceuticals):
Big kudos to Acurx as they hit a milestone! Their Phase 2b clinical trial results for ibezapolstat, aimed at combating C. difficile infections, are now published in Lancet Microbe. This feels like the science nerds just scored an A+ on their final exam! Keep an eye on this one, especially if they keep rolling out wins like this.$VTYX (Ventyx Biosciences):
Ventyx made waves with their initial data on VTX3232. This treatment for early-stage Parkinsonâs might still be in Phase 2a, but early results look promising. Itâs never too late to bet on innovation, and this could be medicineâs next big leap.$AZTR (Azitra):
Netherton syndrome doesnât often make headlines, but Azitra is changing that with safety data from their Phase 1b trial. If you love underdog stories, this oneâs worth watching.$PRPH (ProPhase Labs):
Shoutout to ProPhase for wowing us with their BE-Smartâą testâs esophageal cancer detection abilities. When it comes to conquering cancer diagnostics, innovation gets a standing ovation.
đŒ Big Money Moves
$BKYI (BIO-key):
The International Defense Ministry just handed BIO-key over $600K for their biometric tech. Secure access to critical information? Yes, please. This screams âfuture-proofâ to us, and it might just be the steady investment some portfolios need.$RELI (Reliance Global Group):
Reliance plans to sell Fortman Insurance for $5M in cash. Opinions on divesting? Itâs a bold move, potentially freeing up capital to sharpen their focus. Definitely one to watch for a rebound strategy.
đ Growth and Momentum
$SOAR (Vaunt):
If the name didn't already give it away, Vaunt is, well, soaring. They're projecting a whopping 85% growth in subscriptions. With that kind of demand, it feels like theyâre strapped to a rocket. Donât sleep on this stock.$XAIR (Beyond AirÂź):
Revenue soaring 220% year-over-year? Now thatâs how you get attention. Beyond Airâs LungFitÂź PH is well on its way to making a splash in the respiratory treatment market. Keep your oxygen tanks ready, this oneâs buzzing.
đĄ Other Interesting Plays
$MENS IPO:
Jyong Biotech had a strong debut, halting up 16.5%. This Taiwan-based biotech focuses on plant-based urinary treatments and may just be the green investment your portfolio needs.$BMNR (BitMine Immersion):
Bitcoin buffs, BitMine isnât playing around. Theyâve just stocked up on more BTC, bringing their total to 154.167. With recent market swings, this feels like theyâre gearing up for a comeback ride.$GORV (Lazydays):
Lazydays completed transactions aimed at making their operations more liquid. Could this be their ticket to long-term financial health? Time will tell, but those liquidity plays often carry hidden potential.$PSTV (Plus Therapeutics):
More shares. More warrants. They expanded capital in March 2025 and are firing on all cylinders. Love them or hate them, they know how to raise funds when needed.
Key Takeaway:
This week delivered a mix of breakthroughs, bold bets, and stunning growth stories. From biotech breakthroughs to bullish business moves, every ticker on this list has its own thrilling narrative.
We Want to Hear From You!
Which of these stocks piques your interest? Are you already holding any of them, or tempted to jump in? Feel free to join the discussion in our Stock Region community!
Reminder:
This newsletter is here to keep you informed, but make sure to do your due diligence. The market can be unpredictable, and no one has a crystal ball (as much as we wish we did).
Until next time, happy investing and stay sharp!
Final Disclaimer: All investments carry risks. This is not financial advice. The content herein is for informational and entertainment purposes only. Always consult with a professional before making financial decisions.